John Pinching is an Editor at RamaOnHealthcare and PharmaTimes Media Ltd. He specializes in medicine and healthcare, with a focus on medical specialties such as immunology, immunotherapy, oncology, and pancreatic cancer research, as well as hematology. John’s insightful contributions have been featured in prominent healthcare publications, further establishing his expertise in these critical areas.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
John's coverage heavily focuses on healthcare and pharmaceutical industry, particularly press releases and data citations. He may prefer pitches with access to exclusive data or insights into the latest advancements in pharmaceuticals, medical treatments, clinical trials, mergers and acquisitions within the healthcare sector.
Given his extensive use of press releases as sources for his articles, he may be interested in receiving well-documented pitches with detailed information about newsworthy developments within the healthcare and pharmaceutical industries.
While John does not have a specific geographic focus mentioned, it is evident that his interest lies in global developments within the healthcare and pharmaceutical sectors. Therefore, he would likely appreciate relevant information from experts across different regions impacting these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Pinching
Guidance paves the way for NHS access for eligible adults in England and Wales
By: John Pinching
Study marks major milestone for CTH120 as company advances disease‑modifying ambitions
By: John Pinching
Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial
By: John Pinching
Final draft guidance recommends D‑VRd on the NHS in England and Wales
By: John Pinching
Breakwater phase 3 data show significant gains in progression‑free survival
By: John Pinching
Sanofi therapy becomes first disability‑targeting medicine for nrSPMS
By: John Pinching
FDA alignment secured as company prepares to begin dosing in 2026
By: John Pinching
Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in Geneva.
By: John Pinching
First immunotherapy approved for LACC in England offers new treatment option for women
By: John Pinching
No adverse events observed as study begins in EGFR‑mutant NSCLC
